

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT4376703

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	WOLFGANG LIEDTKE	10/01/2014
	FARSHID GUILAK	09/05/2014
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	Duke University	
<b>Street Address:</b>	2812 Erwin Road	
<b>Internal Address:</b>	Suite 306	
<b>City:</b>	Durham	
<b>State/Country:</b>	NORTH CAROLINA	
<b>Postal Code:</b>	27705	
<b>PROPERTY NUMBERS Total: 1</b>		
<b>Property Type</b>	<b>Number</b>	
<b>Application Number:</b>	15505898	
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>	(414)277-0656	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	(414)271-6560	
<b>Email:</b>	dahausen@michaelbest.com	
<b>Correspondent Name:</b>	MICHAEL BEST & FRIEDRICH LLP	
<b>Address Line 1:</b>	100 EAST WISCONSIN AVENUE	
<b>Address Line 2:</b>	SUITE 3300	
<b>Address Line 4:</b>	MILWAUKEE, WISCONSIN 53202-4108	
<b>ATTORNEY DOCKET NUMBER:</b>	028193-9128-US10	
<b>NAME OF SUBMITTER:</b>	JULIA M. COX	
<b>SIGNATURE:</b>	/julia m. cox/	
<b>DATE SIGNED:</b>	04/20/2017	
<b>Total Attachments: 4</b>		
source=20882676_028193-9128-US10_As_Filed_Assignment#page1.tif		
source=20882676_028193-9128-US10_As_Filed_Assignment#page2.tif		
source=20882676_028193-9128-US10_As_Filed_Assignment#page3.tif		



## ASSIGNMENT

Pursuant to our obligation to Duke University (hereinafter referred to as "Assignee"), a North Carolina non-profit institution having its principal place of business at:

2812 Erwin Road  
Suite 306  
Durham, NC 27705

and for other valuable and sufficient consideration, receipt whereof is hereby acknowledged,  
we:

Wolfgang Liedtke  
11 Altmont Court  
Durham, NC 27705

Farshid Guilak  
~~1614 Pinecrest~~ 16 Lytham Lane  
Durham, NC ~~27705~~ 27707

confirm our obligation to and hereby sell, assign and convey, unto Assignee, its successors and assigns, our entire right, title and interest

(1) in and to inventions described in a patent application titled TRPA1 AND TRPV4 INHIBITORS AND METHODS OF USING THE SAME FOR ORGAN-SPECIFIC INFLAMMATION AND ITCH the specification of which was filed with my authority on August 22, 2014 as International Patent Application No. PCT/US2014/052394 (Atty. File No. 028193-9128-WO01) (hereinafter the "PCT application");

(2) in and to the PCT application, in and to all other U.S. patent applications (including PCT national phase, divisional, continuation, continuation-in-part, §111(b) provisional, §111(a), and reissue applications) based upon said inventions or claiming the benefit of the PCT application, and in and to the patent or patents to be granted thereon, to the full end of the term or terms for which said patent or patents may be granted;

(3) in and to all patent applications on said invention now or hereafter filed in countries foreign to the United States of America, including foreign applications entering the national

phase of the PCT application, and in and to any and all patents granted on said applications to the full end of the terms for which said patents may be granted; and


(4) under the International Convention in respect to the PCT application.

We agree that any patent applications of any foreign countries which may be filed shall be filed in the name of Assignee with a claim to priority based on the PCT application.

We hereby agree that we will, upon demand of Assignee, its successors or assigns, and without further consideration to us, execute any and all papers that may be necessary, or deemed by Assignee, its successors or assigns, to be necessary, to a complete fulfillment of the intent and purposes of this Assignment, it being understood that any expense incident to the execution of such papers shall be paid by Assignee, its successors and assigns, and not by us.

The Commissioner of Patents and Trademarks of the United States is hereby authorized and requested to issue said patent or patents to Assignee.

10.1.14  
\_\_\_\_\_  
Date

  
\_\_\_\_\_  
Wolfgang Liedtke

\_\_\_\_\_  
Date

\_\_\_\_\_  
Farshid Guilak

## ASSIGNMENT

Pursuant to our obligation to Duke University (hereinafter referred to as "Assignee"), a North Carolina non-profit institution having its principal place of business at:

2812 Erwin Road  
Suite 306  
Durham, NC 27705

and for other valuable and sufficient consideration, receipt whereof is hereby acknowledged,  
we:

Wolfgang Liedtke  
11 Altmont Court  
Durham, NC 27705

Farshid Guilak  
~~1614 Pinecrest~~ 16 Lytham Lane  
Durham, NC ~~27705~~ 27707

confirm our obligation to and hereby sell, assign and convey, unto Assignee, its successors and assigns, our entire right, title and interest

(1) in and to inventions described in a patent application titled TRPA1 AND TRPV4 INHIBITORS AND METHODS OF USING THE SAME FOR ORGAN-SPECIFIC INFLAMMATION AND ITCH the specification of which was filed with my authority on August 22, 2014 as International Patent Application No. PCT/US2014/052394 (Atty. File No. 028193-9128-WO01) (hereinafter the "PCT application");

(2) in and to the PCT application, in and to all other U.S. patent applications (including PCT national phase, divisional, continuation, continuation-in-part, §111(b) provisional, §111(a), and reissue applications) based upon said inventions or claiming the benefit of the PCT application, and in and to the patent or patents to be granted thereon, to the full end of the term or terms for which said patent or patents may be granted;

(3) in and to all patent applications on said invention now or hereafter filed in countries foreign to the United States of America, including foreign applications entering the national

phase of the PCT application, and in and to any and all patents granted on said applications to the full end of the terms for which said patents may be granted; and

(4) under the International Convention in respect to the PCT application.

We agree that any patent applications of any foreign countries which may be filed shall be filed in the name of Assignee with a claim to priority based on the PCT application.

We hereby agree that we will, upon demand of Assignee, its successors or assigns, and without further consideration to us, execute any and all papers that may be necessary, or deemed by Assignee, its successors or assigns, to be necessary, to a complete fulfillment of the intent and purposes of this Assignment, it being understood that any expense incident to the execution of such papers shall be paid by Assignee, its successors and assigns, and not by us.


The Commissioner of Patents and Trademarks of the United States is hereby authorized and requested to issue said patent or patents to Assignee.

\_\_\_\_\_  
Date

9/5/14

\_\_\_\_\_  
Date

\_\_\_\_\_  
Wolfgang Liedtke



\_\_\_\_\_  
Farshid Guilak